A Comparative Analysis of D-Mannoheptulose and Trastuzumab in Breast Cancer: Targeting the Warburg Effect versus HER2 Signaling

Abstract

          Background: D-Mannoheptulose (MH) is a hexokinase inhibitor that hampers glycolysis whereas, Trastuzumab (TZB) is an immunotherapeutic drug that causes apoptosis in cancer cells. Interestingly, Cancer cell metabolism modulation serves as one of the excellent targets for treatment translation for the reason that it is capable of preventing cell proliferation. Objective: Aiming to determine the therapeutic prospects of D-Mannoheptulose and Trastuzumab, this study is designed to examine their cytotoxic characteristics against normal and breast cancer cells. Method: MCF-7 breast cancer cell line and Human mammary epithelial cells (HMECS) were cultured by RPMI-1640 and Minimum Essential Medium (MEM). Subsequently, the synthesis of MH and TZB was conducted. Afterwards both cell lines were treated to different doses of the agents prepared. Cellular toxicity was completed via MTT assays. Results: Results showed that both MH and TZB induced significant antimetastatic and antiproliferative activities against breast cancer MCF-7 cells with the IC50 values proving efficacy. In addition, MH and TZB had no observable cytotoxic effects on HMEC which were the healthy and tumor nontarget cells. Conclusion: Through increased cytotoxicity and apoptosis induction, D-Mannoheptulose and Trastuzumab can help deal with the metabolic aspect of tumor cells in Her2 positive breast cancer patients.